Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors

Summary

This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of functionally enhanced ALPP-targeted engineered T Cells (Herein referred to as Enhanced ALPP CAR-T) in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.

Timeline

Start

2026-02-28

Primary completion

2028-02-28

Completion

2029-02-28

Drugs

Indications